2018 IDWeek, the Co-morbidities and Adverse Drug Reactions Workshop, and Glasgow*

Download All
IDWeek 2018; October 3-7, 2018; San Francisco, California
20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; October 13-14, 2018; New York, New York
HIV Drug Therapy Glasgow 2018; October 28-31, 2018; Glasgow, United Kingdom
Review the latest clinical findings from 3 important HIV meetings.

Capsule Summaries

Although tolerability was similar between arms, treatment-emergent resistance arose more frequently at virologic failure with reduced-dose EFV–based vs DTG-based ART.

Released: November 30, 2018

More than three quarters of patients who initiated same-day PrEP during a drop-in STD clinic appointment attended at least 1 PrEP follow-up care visit.

Released: November 16, 2018

Retrospective analysis of multiethnic North American cohort finds greater weight gains with DTG or RAL vs EVG.  

Released: November 6, 2018

Doravirine-based ART was well tolerated with lower rates of neuropsychiatric adverse events and more neutral lipid effects vs efavirenz-based ART in this updated analysis of a phase III noninferiority trial.

Released: October 17, 2018

Noninferior efficacy achieved at Weeks 24 and 48 after switch to new NNRTI-based regimen, compared with continuation of baseline boosted PI–, NNRTI-, or EVG/COBI-based ART.

Released: October 17, 2018

Study finds fewer treatment-related adverse events, less nausea with BIC/FTC/TAF, and no emergent resistance in either arm.

Released: October 17, 2018

In this large observational study, alcohol use during first trimester and tobacco use during first trimester or anytime during pregnancy was also associated with increased risk of neurologic diagnosis among HIV-exposed, uninfected children.

Released: November 8, 2018

Similar low rate of discontinuation for adverse events in both treatment arms and no emergence of resistance in either arm.

Released: November 8, 2018

No treatment-emergent resistance associated mutations to darunavir or tenofovir were observed in evaluable patients with protocol-defined virologic failure.

Released: November 9, 2018

Virologic responses were durable across key subgroups, particularly in female, older, and black participants.

Released: November 13, 2018

In patients with baseline CD4+ cell counts ≤ 200 cells/mm3, numerically lower virologic suppression rates with DTG + 3TC vs DTG + FTC/TDF were generally not related to efficacy or treatment.

Released: November 30, 2018

Only 2 NTD cases were identified in 630 elvitegravir-exposed pregnancies, suggesting a rate similar to that of the general population.

Released: November 9, 2018

Most injection-site reactions were mild or moderate and most resolved quickly with only ~ 1% of patients discontinuing because of these reactions.

Released: November 13, 2018

The proportions of patients with viral blips were statistically similar with switch to BIC/FTC/TAF vs continued boosted PI plus 2 NRTIs; all patients with viral blips had HIV-1 RNA < 50 copies/mL at last on-treatment study visit through Week 48.

Released: November 30, 2018

No patient switching to DRV-based single-tablet regimen discontinued for lack of efficacy during 96-week follow-up.

Released: October 19, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by
Gilead Sciences
Janssen Therapeutics
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.